

Supplementary information

Supplementary Table 1. Median (10th, 90th percentiles) rotavirus antibody levels at entry and post study dose 3^a

Immunologic assay				Placebo				RV5 ^b				Wilcoxon rank sum test			
HIV status		Time point		N	Median	10th	90th	N	Median	10th	90th	HIV+:HEU (All at entry) ^c	HIV+:HEU (RV5) ^d	RV5:Placebo (within HIV- 1 strata) ^e	
Serum anti-rotavirus IgA															
	HEU	Entry PD3	58	1	1	25	59	2	1	35	0.08	0.55			
			58	3	1	257	58	66	5	1137				<0.001	
	HIV+	Entry PD3	33	2	1	86	35	2	1	127			<0.001		
			33	2	1	267	35	119	7	625					
Serum Neutralizing Antibody															
SNA G1	HEU	Entry PD3	58	38	13	154	59	42	15	130	0.001	0.92	<0.001		
			58	18	10	48	58	53	14	452					
	HIV+	Entry PD3	33	24	12	91	35	25	12	95			<0.001		
			33	15	10	28	35	61	14	324					
SNA G2	HEU	Entry PD3	58	48	16	139	59	62	21	135	<0.001	0.33	0.015		
			58	21	10	105	58	35	11	167					
	HIV+	Entry PD3	33	29	11	100	35	25	10	118			0.35		
			33	23	10	73	35	23	10	749					
SNA G3	HEU	Entry PD3	58	17	10	200	59	28	10	164	<0.001	0.33	<0.001		
			58	10	10	40	58	22	10	159					
	HIV+	Entry PD3	33	13	10	45	35	12	10	40			<0.001		
			33	10	10	12	35	15	10	105					
SNA G4	HEU	Entry PD3	58	55	19	152	59	67	16	178	<0.001	0.65	<0.001		
			58	24	12	101	58	84	26	297					
	HIV+	Entry PD3	33	27	12	82	35	17	10	56			<0.001		
			33	15	10	62	35	101	15	464					
SNA P1	HEU	Entry PD3	58	67	13	459	59	87	13	311	<0.001	0.11	0.003		
			58	25	10	263	58	60	16	539					
	HIV+	Entry PD3	33	31	10	200	35	32	11	182			0.015		
			33	12	10	145	35	34	10	645					

Lower and upper limits for serum anti-rotavirus IgA: 1.152 and 1250 (dilution=20).

Lower and upper limits for each serum neutralizing antibody (SNA): 10 and 1280 (dilution=2).

Lower limit for rotavirus IgA copro-antibody assay: 0.35 units/ml.

Results were similar when the five participants with pre-dose values greater than 1/3ULOQ were classified as non-responders and when they were classified as responders and included in the analysis.

^a Per protocol population.


^b RV5 = pentavalent rotavirus vaccine.

^c Comparison of pre-entry levels by HIV status.

^d Comparison of postdose 3 levels by HIV status in RV5 recipients.

^e Comparison of postdose 3 levels within HIV stratum between RV5 and placebo.

A. Gating strategy for panels 1 and 2.




Upper panels show the gating on CD4+ and CD8+ T cells.

Middle panels show an example of gating for panel 1, which included CD3, CD8, HLADR, CD38, CD25 and FOXP3. The panels show gating on CD38+HLADR+ CD8 cells. Similar strategy was used for CD4 cells and for FOXP3 and CD25 both on CD4 and CD8 cells.

Lower panels show an example of gating for panel 2, which included CD3, CD8, CD19, IL10, TGFb and IL17. Due to the small number of events in the TGFb and IL-10 gates, the TGFb+IL10+ population was not evaluated in our comparisons.

B. Gating strategy for panel 3



Upper panels show gating the CD19+ B cells

Lower left panel shows gating on CD10+ (left). Lower right shows gating on CD21 and CD27 pos and neg populations out of the CD19+CD10- B cells.